O'Connor Daniel J.'s Form 4 filing
Ambrx Biopharma, Inc. (AMAM) · filed Oct 31, 2023
- Accession no.
- 0000950170-23-056943
- Filed
- Oct 31, 2023
- Trade date
- Oct 27, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $491.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| O'Connor Daniel J.CIK 0001376847 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 27, 2023 | Common Stock | SSaleDisposed | −50,012 | $9.82F3 | −$491,117.84 | 342,845 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.70 to $9.99. The Reporting Person undertakes to provide to Ambrx, any security holder of Ambrx or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.